BACKGROUND: Heart health benefits have been attributed to regular consumption of oats. Preclinical evidence suggests that a wild green oat extract (WGOE) may improve vasodilator function, but this is yet to be evaluated in humans. OBJECTIVE: To determine whether regular daily consumption of WGOE can influence vasodilator function in systemic and cerebral arteries. METHODS:Thirty-seven healthy older adults (>60 years) completed a 24-week randomized, double-blind, placebo-controlled two-way crossover dietary intervention with 1500 mg/day of encapsulated WGOE or placebo. All assessments were conducted at the end of each 12-week intervention arm, after participants had fasted for at least 4 h and at least 18 h after they had taken their last dose of supplement. Flow-mediated dilatation (FMD) of the brachial artery and hypercapnia-induced increases of blood flow in the middle cerebral artery were used to measure systemic and cerebral vasodilator responsiveness (CVR), respectively. RESULTS: Compared with placebo, WGOE supplementation increased CVR and FMD to a similar extent (42 and 41%, respectively, P < 0.01 for both). The improvements in CVR and FMD were not correlated. Resting blood pressure did not alter with supplementation. Dose and treatment duration were well tolerated by participants. CONCLUSION:WGOE supplementation can improve vasodilator function in systemic and cerebral arteries, suggesting a potential role in the maintenance of cardiovascular health.
RCT Entities:
BACKGROUND: Heart health benefits have been attributed to regular consumption of oats. Preclinical evidence suggests that a wild green oat extract (WGOE) may improve vasodilator function, but this is yet to be evaluated in humans. OBJECTIVE: To determine whether regular daily consumption of WGOE can influence vasodilator function in systemic and cerebral arteries. METHODS: Thirty-seven healthy older adults (>60 years) completed a 24-week randomized, double-blind, placebo-controlled two-way crossover dietary intervention with 1500 mg/day of encapsulated WGOE or placebo. All assessments were conducted at the end of each 12-week intervention arm, after participants had fasted for at least 4 h and at least 18 h after they had taken their last dose of supplement. Flow-mediated dilatation (FMD) of the brachial artery and hypercapnia-induced increases of blood flow in the middle cerebral artery were used to measure systemic and cerebral vasodilator responsiveness (CVR), respectively. RESULTS: Compared with placebo, WGOE supplementation increased CVR and FMD to a similar extent (42 and 41%, respectively, P < 0.01 for both). The improvements in CVR and FMD were not correlated. Resting blood pressure did not alter with supplementation. Dose and treatment duration were well tolerated by participants. CONCLUSION: WGOE supplementation can improve vasodilator function in systemic and cerebral arteries, suggesting a potential role in the maintenance of cardiovascular health.
Authors: Michelle N McDonnell; Narelle M Berry; Mark A Cutting; Hannah A Keage; Jonathan D Buckley; Peter R C Howe Journal: PeerJ Date: 2013-04-09 Impact factor: 2.984
Authors: David O Kennedy; Bernd Bonnländer; Stefanie C Lang; Ivo Pischel; Joanne Forster; Julie Khan; Philippa A Jackson; Emma L Wightman Journal: Nutrients Date: 2020-05-29 Impact factor: 5.717